Nov 3, 2014 | Daniel B. Goodman, MD, and Michael A. Weber MD

Blood Pressure Evaluation During Early Phase Trials

As we know, more attention is being paid to blood pressure (BP) effects in new chemical entities under development for non-hypertension indications, especially when these are not anticipated or thoroughly defined during drug development. Discovering negative results for BP elevation in early trials, would allow more informed planning for BP safety monitoring in later trials.

Download the publication to discover a systematic approach to identifying blood pressure effects during typical Phase I and Phase II trials, including: